Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/
Location: Netherlands, Utrecht
Employees: 51-200
Total raised: $157.12M
Founded date: 2003
Investors 6
| Date | Name | Website |
| 20.05.2025 | Avoro Capi... | avorocapit... |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
| - | Aglaia Onc... | aglaia-onc... |
| - | Bay City C... | baycitycap... |
| - | Life Scien... | lspvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 26.08.2015 | Series C | $82.49M | - |
| 20.05.2015 | Grant | $2.33M | - |
| 03.10.2013 | Series B | $42.17M | - |
| 29.01.2010 | Series B | $30.13M | - |
Mentions in press and media 31
| Date | Title | Description |
| 01.04.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments increases NAV by 17.2 percent and expects annual profit of CHF 272 million for the 2025/2026 financial year | HBM Healthcare Investments, an investment company specializing in the healthcare sector, successfully closed its 2025/2026 financial year as of 31 March. Over the course of the year, the net asset value (NAV) in Swiss francs increased by 17... |
| 13.01.2026 | Kinaset Therapeutics Secures $103M for Severe Asthma Drug Advancement | Kinaset Therapeutics obtained $103 million in Series B funding. This capital fuels the development of frevecitinib. Frevecitinib is an innovative inhaled pan-JAK inhibitor. It targets severe asthma and other serious respiratory diseases. Th... |
| 12.01.2026 | Kinaset Therapeutics Raises $103M in Series B Funding | Kinaset Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $103M in Series B funding. The round was led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life ... |
| 10.01.2026 | Kinaset Therapeutics: $103 Million Series B Closed To Advance Inhaled Pan-JAK Drug For Severe Asthma | Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B financing to fund mid-stage development... |
| 14.11.2025 | Medicxi Closes €500 Million Fund To Advance Asset-Centric Biotech Innovation | Medicxi announced the close of its €500 million Medicxi V vehicle, reinforcing the firm’s position as a major European life sciences investor and adding significant capital to expand its long-standing asset-centric company creation strategy... |
| 29.09.2025 | Stocks making the biggest moves midday: CSX, Electronic Arts, Pony AI, Merus and more | - |
| 29.09.2025 | Датская Genmab покупает нидерландскую фармкомпанию Merus за $8 млрд | Genmab выкупит акции Merus по цене $97 за штуку наличными, говорится в совместном заявлении компаний в понедельник. Это примерно на 41% выше цены закрытия акций Merus, котирующихся в США, по состоянию на 26 сентября. Ранее Bloomberg News со... |
| 29.09.2025 | Genmab to Acquire HBM Portfolio Company Merus for USD 8 billion in Cash | HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its listed portfolio company, Merus (Nasdaq: MRUS), has entered into a transaction agreement with Genmab (Nasdaq: GMAB). Genmab intends to acquire... |
| 28.09.2025 | S&P 500 closes higher as AI leader Nvidia rebounds, EA surges on takeover | The S&P 500 rose on Monday as Wall Street regained some of its footing after a week in which the artificial intelligence trade lost a bit of steam. The broad market index climbed 0.26% to finish at 6,661.21, and the Nasdaq Composite adv... |
| 12.08.2024 | Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates | USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 12, 2024 /PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to impro... |
Show more